A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Indoles
  • Melanoma
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • ADI-PEG 20 was well tolerated in combination with gemcitabine and nab-paclitaxel. Activity was observed in previously treated and untreated patients with advanced pancreatic cancer and in patients with ASS1-deficient and -proficient tumors. Cancer 2017. © 2017 American Cancer Society.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.30897

PubMed ID

  • 28832976

Additional Document Info